Boehringer Ingelheim has a large and experienced global team managing and conducting clinical trials in many indications. During the past decade from 2004 to 2013 Boehringer Ingelheim conducted or sponsored 1.377 studies with 119 substances in 98 countries from all regions of the world.
In compliance with our Policy on Transparency and Publication of Clinical Study Data, we are committed to disclosing all study results independent of outcome. We support responsible sharing of de-identified clinical study data and redacted clinical documents, if data are available in our Clinical Trial Data Database or as reports following the ICH E3 format.
Access is provided after regulatory review has been completed or after termination of the drug development program and once the primary manuscript describing the results has been accepted for publication.
We post study result synopses in ICH E3 summary format on this website within one year after completion of the study once the product is approved in at least one country. We also provide a list of study related publications.
We provide redacted Clinical Study Reports and related clinical documents on request, based on a "Document Sharing Agreement" only for scientific purposes.Please specify your request according to the categories listed below.
Patient level study data provide opportunities to conduct further research that can help advance medical science or improve patient care. Researchers can use this external plattform to request access to raw data from our clinical studies.